Full video transcriptClick to expand
Auto-generated transcript of @aprnmyers's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Now this is unreal. When I started to set the tide, I was at 203 pounds. Now I'm down to 181.
- 0:10And then I'm going into my, I did the seventh shot last week. So this week I'm going to do the eighth
- 0:17shot. Look, I can't believe it. I mean, I was taught 3, but I didn't look like 2 or 3. I didn't
- 0:27look like I was taught. I kind of carried my weight well. But I am like so amazed at the results. Look,
- 0:35look. And the thing is, I started, I started the Tercepti because I was born with Jamaica my
- 0:42birthday is next month. And I wanted to lose the weight for Jamaica. But you know what's the problem
- 0:51now? Notice I've lost the weight on my hair. Look at my ass. Let it have lost the weight. I have
- 0:56to buy new clothes because they're not fitting. I tried on something and it's too big. So now,
- 1:05new problem, I have to buy different clothes. My only regret with this medication is that I didn't
- 1:10start it sooner. I know some people have, you know, hung up like, why do meds? You know, why not do
- 1:16it in the natural way going, you know, watch what to eat, exercise. But as you get older, it's more
- 1:24difficult for women, especially to lose weight. And I tried for years, I go back and forth
- 1:29struggling to lose weight during the gym, pay training. And so this was my last resort. And
- 1:36I have like, I know I look a mess. I have like no regrets. Look at that. Look at that. I have no
- 1:42regrets whatsoever. We'll do it again in a heartbeat.
Tirzepatide weight loss results: what TikTok shows vs. trial data
Quick answer
The creator reports a 22-pound weight reduction over approximately 7-8 weeks of tirzepatide injections, starting at 203 pounds. She also reports hair loss, consistent with telogen effluvium secondary to rapid caloric deficit, a common and typically temporary condition. No doses, brand names, or specific injection protocols are mentioned in the video, keeping it within the bounds of a personal testimonial rather than clinical instruction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide weight loss results: what TikTok shows vs. trial data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tirzepatide weight loss results: what TikTok shows vs. trial data" from APRNmyers123. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports a 22-pound weight reduction over approximately 7-8 weeks of tirzepatide injections, starting at 203 pounds.
The reason this review is not generic is the source wording and the canonical claim label "glp1 tirzepatide weightloss weightlosstransformation fyp foryoupa." In this clip, the useful excerpt is: "Now this is unreal." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator reports a 22-pound weight reduction over approximately 7-8 weeks of tirzepatide injections, starting at 203 pounds.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator reports a 22-pound weight reduction over approximately 7-8 weeks of tirzepatide injections, starting at 203 pounds. She also reports hair loss, consistent with telogen effluvium secondary to rapid caloric deficit, a common and typically temporary condition. No doses, brand names, or specific injection protocols are mentioned in the video, keeping it within the bounds of a personal testimonial rather than clinical instruction.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide at the highest dose produced a mean 22.5% body weight reduction over 72 weeks in a randomized trial of over 2,500 participants.
- Hair loss during rapid weight loss is typically telogen effluvium, not a direct drug toxicity, and is usually temporary but should be discussed with a prescriber before it becomes a surprise.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide at the highest dose produced a mean 22.5% body weight reduction over 72 weeks in a randomized trial of over 2,500 participants.
- Hair loss during rapid weight loss is typically telogen effluvium, not a direct drug toxicity, and is usually temporary but should be discussed with a prescriber before it becomes a surprise.
- SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who stopped tirzepatide regained approximately two-thirds of lost weight within one year. Stopping the drug is not a neutral act.
- Tirzepatide received FDA approval for chronic weight management as Zepbound in November 2023, separate from its earlier approval as Mounjaro for type 2 diabetes.
- Age-related metabolic slowdown in women is real and supported by longitudinal research, making the creator's framing of her own situation scientifically grounded, not an excuse.
- Individual results in testimonial videos are not clinical benchmarks. Early rapid loss often includes a fluid component, and results shown at 7-8 weeks do not reflect long-term maintenance trajectories.
- Tirzepatide carries a boxed warning for potential thyroid C-cell tumor risk based on rodent data. Anyone with a personal or family history of medullary thyroid carcinoma should not use this drug.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @aprnmyers actually say?
The creator, who identifies as an APRN, says she started tirzepatide at 203 pounds and dropped to 181 over roughly seven weeks of injections. She frames the drug as a "last resort" after years of failed diet and exercise attempts, and argues that weight loss becomes harder for women as they age. Her only stated regret: not starting sooner.
This is a first-person testimonial, not a clinical recommendation. She is not prescribing doses, not naming a brand or compounded version specifically, and not claiming the drug treats any disease. That keeps her on reasonably safe ground, at least legally. But testimonials carry their own risks: 22 pounds in seven shots is fast enough to raise questions about context, and the comment about hair loss is worth unpacking separately.
Does the science back this up?
The broad strokes, yes. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and the clinical evidence for weight loss is among the strongest we have seen in this drug class. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed participants on the highest dose losing a mean of 22.5% of body weight over 72 weeks. That is not a testimonial, that is a randomized controlled trial with over 2,500 participants.
A 22-pound loss in roughly 7-8 weeks is faster than average trial data suggests, but individual responses vary considerably. Starting weight, metabolic history, diet, and activity all affect the curve. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) confirmed that stopping tirzepatide leads to weight regain, which is relevant context missing from this video. The science supports the drug's efficacy. It does not guarantee any individual result.
What did they get wrong (or right)?
She is largely right that weight loss becomes harder for women with age. Menopause-related hormonal shifts reduce resting metabolic rate and increase visceral fat accumulation, a pattern documented in longitudinal data (Guo et al., 1999, International Journal of Obesity). Calling it "more difficult for women, especially" as they age is not a myth. It is a documented physiological reality.
The hair loss comment is where things get interesting. She seems surprised by it. She should not be. Telogen effluvium, or stress-induced shedding, is a well-documented side effect of rapid weight loss regardless of method. A review by Guo and Katta (2017, Dermatology Practical and Conceptual) confirmed that caloric restriction and rapid mass loss trigger this shedding. It is temporary in most cases, but her framing suggests she was not warned. That is a gap in pre-prescribing counseling, not a drug failure.
What she got right: acknowledging that this was her "last resort" after structured attempts with gym and personal training. That is honest. GLP-1 class drugs are clinically appropriate for patients who have not responded to lifestyle intervention alone, per FDA labeling criteria.
What should you actually know?
A few things the video does not cover. First, tirzepatide is not weight-loss magic with no downside. The SURMOUNT trials documented nausea, vomiting, diarrhea, and constipation as common side effects. The hair loss she mentioned is real and underreported in social content. Second, results shown in a 7-week TikTok are not representative of average outcomes. Rapid early loss often reflects fluid changes alongside fat loss, especially in the first month.
Third, and this is the part social media glosses over: the SURMOUNT-4 data showed that one year after stopping tirzepatide, participants regained about two-thirds of their lost weight. The drug works while you are on it. That is a long-term conversation you should have with a prescriber, not a TikTok comment section.
- Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound, as of November 2023.
- It is not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma.
- Hair loss during rapid weight loss is typically temporary but should be discussed with your provider if it persists.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
APRNmyers123 · TikTok creator
922.4K views on this video
#tirzepatide #weightloss #weightlosstransformation #fyp#foryoupage
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide at the?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide at the highest dose produced a mean 22.5% body weight reduction over 72 weeks in a randomized trial of over 2,500 participants.
What does the video say about hair loss during rapid weight loss?
Hair loss during rapid weight loss is typically telogen effluvium, not a direct drug toxicity, and is usually temporary but should be discussed with a prescriber before it becomes a surprise.
What does the video say about surmount-4 (aronne et al., 2024, jama) found?
SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who stopped tirzepatide regained approximately two-thirds of lost weight within one year. Stopping the drug is not a neutral act.
What does the video say about tirzepatide received fda approval for chronic weight management as zepbound?
Tirzepatide received FDA approval for chronic weight management as Zepbound in November 2023, separate from its earlier approval as Mounjaro for type 2 diabetes.
What does the video say about age-related metabolic slowdown in women?
Age-related metabolic slowdown in women is real and supported by longitudinal research, making the creator's framing of her own situation scientifically grounded, not an excuse.
What does the video say about individual results in testimonial videos?
Individual results in testimonial videos are not clinical benchmarks. Early rapid loss often includes a fluid component, and results shown at 7-8 weeks do not reflect long-term maintenance trajectories.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by APRNmyers123, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.